AIG
CRVS icon

American International Group’s Corvus Pharmaceuticals CRVS Stock Holding History

American International Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-8,843
Closed -$36K – 3115
2019
Q1 		$36K Sell
8,843
-287
-3% -$1.21K ﹤0.01% 2940
2018
Q4 		$34K Sell
9,130
-70
-0.8% -$477 ﹤0.01% 2961
2018
Q3 		$79K Buy
9,200
+166
+2% +$1.66K ﹤0.01% 2938
2018
Q2 		$99K Buy
9,034
+3,647
+68% +$40.7K ﹤0.01% 2789
2018
Q1 		$62K Sell
5,387
-289
-5% -$2.73K ﹤0.01% 2845
2017
Q4 		$59K Buy
5,676
+28
+0.5% +$359 ﹤0.01% 2913
2017
Q3 		$90K Buy
5,648
+422
+8% +$5.84K ﹤0.01% 2699
2017
Q2 		$63K Buy
5,226
+3,176
+155% +$33.9K ﹤0.01% 2936
2017
Q1 		$43K Buy
2,050
+140
+7% +$2.19K ﹤0.01% 2867
2016
Q4 		$27K Sell
1,910
-5
-0.3% -$76 ﹤0.01% 2947
2016
Q3 		$31.5K Buy
1,915
+2
+0.1% +$29 ﹤0.01% 2969
2016
Q2 		$27.3K Buy
+1,913
New +$25.8K ﹤0.01% 3036

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American International Group's CRVS Position: Q2 2019 in Review

American International Group sold out of Corvus Pharmaceuticals (CRVS) in Q2 2019, closing a stake of 8,843 shares — an estimated $36K sold.

American International Group first reported a position in CRVS in Q2 2016 and held it in 12 quarters. The position peaked at $99K in Q2 2018. 45 funds tracked by Wall St. Rank hold CRVS as of Q2 2019.

  • American International Group reported no remaining Corvus Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • American International Group sold 8,843 Corvus Pharmaceuticals shares in Q2 2019, an estimated $36K.
  • American International Group first reported a position in Corvus Pharmaceuticals in Q2 2016 and held it in 12 quarters.
  • American International Group's Corvus Pharmaceuticals position peaked at $99K in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2019.

Based on American International Group's 13F filing for Q2 2019, filed 13 Aug 2019.